First Tracks Biotherapeutics TRAX
NASDAQ TRAX
$46.56 -0.54 (-1.15%)
At close: Nov 16, 2026 · 4:00 PM EST

First Tracks Biotherapeutics (TRAX) Cash from Discontinued Operations (2025 - 2026)

Updated

First Tracks Biotherapeutics' Cash from Discontinued Operations came in at -$32.56 million for Q1 2026, compared with -$45.01 million a year earlier.

Analysis

First Tracks Biotherapeutics (TRAX) Cash from Discontinued Operations (2025 - 2026) Analysis & Trends

For FY2025, First Tracks Biotherapeutics' Cash from Discontinued Operations was -$142.93 million.

  • Going back by year, Cash from Discontinued Operations was -$125.81 million in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discont. Ops (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn -
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn -
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn -
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn 6.56 Bn
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn -
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn -
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn -
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn -
10 First Tracks Biotherapeutics 1.66 Bn 740.14 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -32.56 Mn
Mar 31, 2025 -45.01 Mn
API Access

First Tracks Biotherapeutics Cash from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-discontinued-operations&ticker=TRAX&period=max&api_key=YOUR_API_KEY